Don’t forget significant fibrosis with ILD has +RCT with nintedanib INBUILD study. Lots of buzz of RA ILD where MTX is OK, TNFi may have more ILD than other bDMARDs, biomatkers KL-6 @eular_org OP0038 #EULAR2020 @CRASCRRheum https://t.co/OihF3LmNYQ

#Upadacitinib #psoriaticarthritis Upa works in PsA including imaging and when they show it surprising good PASI scores as well https://t.co/ZWqj8ythHB

#guselkumab #axialdisease - who would have thunk it - IL23 p19 works in axial involvement PsA with radiology! https://t.co/TaSFBJFRnx

H2H UPA vs ABA RCT; UPA is clinically superior to ABA in DAS-CRP remission, ACR50, ACR70 at wk 12/24 (NOT diff in Pain, FACIT, Boolean remission); But UPA has more serious AE (vs ABA) - esp hepatic, OI, SIE, SAE, CPK (but not zoster VTE) #EULAR20 SAT0151 https://t.co/K96lybdg7L https://t.co/vQM2MSCNzD

• https://bit.ly/3eXAaYu

Dr Mariette summarizes the evidence for using cytokine-targeted therapies in #COVIDー19 Several studies with favorable results with #Tocilizumab and #Anakinra, however, almost all with methodological limitations (e.g., historical groups) #EULAR2020 #EULAR20 #EULAR2020goesvirtual https://t.co/cMUKoeGfK9

MAINRITSAN3 RCT, RTX v PLBO in AAV 28mo relapse free survival ⬇️ RTX (96% vs 74%, NNT~4), majr (100% vs 87%, NNT~8) 1. Selected grp (all pts from MAINRITSAN2) 2. All pts had GC q3mos - IRL benefit could be bigger? Strong data for RTX >2yrs in AAV PDF: https://t.co/Mbrq7bFHk0 https://t.co/auKJ3QPKr0

• Articles I Have Tweeted About - Organized by Date - Google Drive

Drug retention rates & treatment outcomes in 1,860 axSpA patients Rx with secukinumab in routine clinical practice in 13 European countries in the EuroSpA research collaboration network -> registry data drug retention rates THU0398 @RheumNow #EULAR2020 https://t.co/x3Y4tMetij https://t.co/DkUyIfyWwS

• EULAR Abstract Archive

Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data from the double-blind, randomized Tortuga trial #EULAR2020 @rheumnow THU0377 https://t.co/1b18Uyvo5j https://t.co/zBXCwGc0Q7

• EULAR Abstract Archive

Integrated safety analysis of filgotinib treatment for RA from 7 clinical trials: 4,057 patients, VTE risk looks very reassuring #EULAR2020 @RheumNow https://t.co/Ld2tpu7UT5 https://t.co/sZqadeUTh8

• EULAR Abstract Archive

Secukinumab in nr-axSpA, in a mostly biologic naive cohort was effective: ASAS40 response of ~42%, data from the Phase III prevent trial Abstract OP0106 #EULAR2020 @rheumnow https://t.co/KATpGJs2y9 https://t.co/zeBFS2pMl0

• E-CONGRESS